VEGFA and hepatocellular carcinoma: Moreover, SAF-AuNPs/DOX-AuNPs combination therapy revealed a significant reduction in the VEGF percentage of positive cells than HCC group (p < 0.001) and either SAF-AuNPs or DOX-AuNPs (p < 0.001) groups (Fig. 11b).